Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976070 | 0.89 | MAPT (0.60) | MAPTDDB1CRBNGPR119OPRM1 | |
| SCHEMBL4980291 | 0.86 | HSP90AA1 (0.55) | MAPTHSP90AA1HSP90AB1OGA | |
| SCHEMBL30405602 | 0.85 | MAPT (1.00) | MAPTHSP90AB1GPR119 | |
| SCHEMBL30363533 | 0.83 | MAPT (0.81) | MAPTHSP90AA1HSP90AB1GPR119OGA | |
| SCHEMBL21527992 | 0.83 | MAPT (0.81) | MAPTHSP90AA1HSP90AB1GPR119OGA | |
| SCHEMBL1017921 | 0.83 | MAPT (0.77) | MAPTHSP90AA1HSP90AB1 | |
| SCHEMBL31046962 | 0.83 | MAPT (0.77) | MAPTHSP90AA1HSP90AB1DDB1CRBN | |
| SCHEMBL21528007 | 0.83 | MAPT (0.77) | MAPTHSP90AA1HSP90AB1DDB1CRBN | |
| SCHEMBL31590824 | 0.81 | MAPT (0.71) | MAPTHSP90AB1DDB1CRBNGPR119 | |
| SCHEMBL21528083 | 0.80 | MAPT (0.72) | MAPTHSP90AA1HSP90AB1OGAESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029588-A4 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORP (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2029588-A2 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | Neurogen Corporation (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| WO-2007146122-A2 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | MAPT 2301/4885HSP90AA1 2689/4885HSP90AB1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.